CARB-X

CARB-X is excited to welcome its newest funder! The Government of #Italy announced a commitment of US$21 million over the next three years to CARB-X at the G7 Joint Finance Health and Ministers’ Meeting last week. New funding from Italy will enhance CARB-X’s efforts to support, accelerate, and coordinate the early-stage development of innovative products aimed at preventing, diagnosing, and treating drug-resistant bacterial infections, a leading cause of death around the world, particularly in low- and middle-income countries (LMICs). “We are profoundly grateful to the Italian Government for their generous support,” said Kevin Outterson, Executive Director of CARB-X and Austin B. Fletcher Professor of Law at Boston University. “Italy’s investment is a powerful addition to the support we receive from a global consortium of funders, including other G7 governments and leading global health foundations. This collective effort underscores the critical importance of international collaboration in the fight against antimicrobial resistance. Together, we are driving innovation and ensuring that the most promising research can be translated into life-saving treatments for patients worldwide.”    🔗 Read our press release here: bit.ly/3UckAiJ   #AMR #StopSuperBugs #AntimicrobialResistance #G7 #Medicine #GlobalHealth

🗞️ New interview! CARB-X Executive Director and Austin B. Fletcher Professor of Law at Boston University Kevin Outterson spoke with Boston University's research news publication The Brink to discuss the Government of #Italy’s new funding commitment to CARB-X. Prof. Outterson highlighted the progress CARB-X has made since it was founded in 2016. Half of all highly innovative new therapeutics for the most dangerous bacterial infections in Phase 1 clinical trials worldwide came through CARB-X. He also emphasized the importance of international collaboration to address antimicrobial resistance. “Because antibiotics are commonly used across the globe for human and animal health, the fight against resistance requires a collaborative, transdisciplinary approach,” said Prof. Outterson. “We also need research from all corners of the world, all hands on deck, to discover and develop novel antibiotics with unique mechanisms of action to treat infections and address resistance.” 🔗 Read here: bit.ly/3A0azOP #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology 

📘 New publication! CARB-X Chief Scientific Officer Richard Alm co-authored an article in The Lancet that analyzes traditional antibacterial products in the drug development pipeline against pathogens on the World Health Organization's list of bacterial priority pathogens. The authors found that the current pipeline is still insufficient to address antimicrobial resistance and noted a major gap exists in the development of traditional antibacterial products with activity against pathogens broadly resistant to existing antibacterial drugs. 🔗 Read here: bit.ly/48iOpDS #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology 

Boston University’s CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a nonprofit dedicated to addressing the global threat of #antimicrobialresistance (AMR), has just received a $21 million boost from the Italian government. This funding will support the development of new antibiotics, vaccines, and diagnostics to combat infections that no longer respond to traditional treatments. The announcement was made at the G7 Joint Finance and Health Ministers’ Meeting, underscoring Italy’s leadership in tackling #AMR, described by Italian Health Minister Orazio Schillaci as "a silent enemy" and a growing global emergency. 🌎 CARB-X, based at the Boston University School of Law, is a global leader in supporting research projects in 13 countries, advancing over 100 projects since its 2016 inception. With backing from several governments, including the United States, Germany, United Kingdom, Canada, and organizations such as the Wellcome Trust, the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation, CARB-X is driving innovation in AMR solutions. Kevin Outterson, CARB-X’s executive director and Austin B. Fletcher Professor of Law at BU, praised Italy’s commitment, noting that international collaboration is key to advancing lifesaving treatments worldwide. 👏 ➡️ http://spr.ly/6005q2EVF

We welcome the Government of Italy as the newest CARB-X co-funder to combat antimicrobial resistant (#AMR) threats. Through our partnership with CARB-X and its funders, we are responding together to the global threat of AMR through supporting the development of early-stage therapeutic, vaccine, and diagnostic candidates. To-date, CARB-X has invested more than $490 million to support more than 100 innovative projects to address AMR. 

CARB-X Executive Director Kevin Outterson participated in Driving Action: Innovation & Access for Resilient Responses Against AMR, a World Health Summit panel co-hosted by CARB-X and IFPMA last week. Outterson spoke about progress made in recent years and the outlook for the antibiotic pipeline. There’s still an urgent need for more sufficient measures to strengthen the pipeline and address the talent crisis in the industry. “If we don’t act with sufficient push and pull incentives, the pipeline essentially collapses within four to eight years,” said Outterson. “There’s motion, but time is running short.” 🔗 Watch the panel here: bit.ly/402oGgW #WorldHealthSummit2024 #WHS2024

CARB-X support for product developers goes beyond funding, providing them with necessary scientific, business, and regulatory advice to navigate product development. The CARB-X Comprehensive Support Model saves product developers time and money while advancing products more quickly to patients. Bolstered by an internal R&D core team with decades of experience from both large and small companies, the CARB-X Support Model connects experts with innovators, bridges science and knowhow, and creates an ecosystem where progress meets possibility to address the global threat of antimicrobial resistance. “Overall, we’re very grateful for the support,” said one product developer. “It’s difficult to work on a program like this with a small company without the support from CARB-X.” 🔗 Learn more about our Support Model here: bit.ly/3zu7l5W #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #Antibiotics

Join CARB-X Executive Director Kevin Outterson for a panel discussion co-hosted by CARB-X and IFPMA at the World Health Summit! The panel will focus on the need for developing new antibiotics to tackle #AMR and explore the path forward for improving the innovation outlook and patient access to new antibacterial products.    📆 Mon. October 14  ⏰ 2 pm CET  🔗 Watch the live stream: bit.ly/402oGgW    #WorldHealthSummit2024 #WHS2024 

Extremely pleased to have delivered the keynote speech at the CARB-X Product Developer conference in Porto last September highlighting the challenges faced by HCPs, parents, and patients in accessing life-saving interventions and diagnostics. Even more pleased with the efforts by CARB-X at addressing these challenges in collaboration with partners, developers, and funders

I had the chance to speak at the CARB-X product developer meeting about the ways in which the program has added value beyond the funding. Preparing for the talk gave me an opportunity to reflect on how much being a part of CARB-X has shaped our program management and expertise development as an organization. It forced us to add rigor to our milestones, document our methods and performance at each stage of development, and expanded our access to expertise that we sorely needed. We started off with some strong skills but a lot of naivety about so many topics, like the web of competing regulations on AST testing. Our CARB-X advisors Betsy Wonderly Trainor Peter J. Dailey Tom Lowery Linda Miller Richard Alm and the Biomedical Advanced Research and Development Authority (BARDA) representatives who follow our program challenged us with their questions, initial skepticism, and clinical/market experience. Today, I consider our team to be world class experts in all of the critical domains we touch because we were pushed to become so by CARB-X. It’s been an honor to be one of their #diagnostic portfolio companies. Thanks to Kevin Outterson Erin Duffy for their leadership. Boston University School of Law National Institute of Allergy and Infectious Diseases (NIAID) Bill & Melinda Gates Foundation Wellcome Trust Bundesministerium für Bildung und Forschung UK Health Security Agency Novo Nordisk Foundation Government of Canada